ArticleRespiratory research2026
Real-world comparison of shape-sensing robotic-assisted bronchoscopy and virtual bronchoscopic navigation for peripheral pulmonary lesions: a propensity score-matched study.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sensitivity for Malignancy with Navigation Bronchoscopy in Small Lung Nodules.Advances in respiratory medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRobotic-assisted bronchoscopy (RAB) may improve diagnosis of peripheral pulmonary lesions (PPLs), particularly when lesion localization and sampling are technically demanding. However, direct real-world comparisons between shape-sensing RAB (ss-RAB) and virtual bronchoscopic navigation (VBN) remain limited.
methodsWe retrospectively reviewed patients who underwent navigational bronchoscopy for PPLs at a single center. Propensity score matching (PSM) was used to balance baseline characteristics between the ss-RAB and VBN groups. Diagnostic yield, tool-in-lesion (TIL) rate, sensitivity for malignancy, adverse events, and learning curves of ss-RAB were evaluated. Learning curves were assessed using cumulative sum analysis based on procedure time and diagnostic success.
resultsFollowing 1:1 PSM, 234 patients were included, with 117 in each group. Final malignancy prevalence was 74.8% overall. Diagnostic yield was higher with ss-RAB than with VBN (85.5% vs. 70.1%; OR 2.39, 95% CI 1.25-4.56). TIL rate was also more frequently achieved with ss-RAB (99.1% vs. 88.9%). Sensitivity for malignancy was 95.6% for ss-RAB compared with 81.2% for VBN. The diagnostic advantage of ss-RAB was most evident in small (< 15 mm), peripheral, bronchus-sign-negative, and upper-lobe lesions, whereas performance was similar in larger or more central nodules. Procedure-related complications were infrequent and comparable between groups. Learning-curve analysis for ss-RAB showed a reduction in procedure time after approximately 23 cases and an earlier improvement in diagnostic success around the 13th case.
conclusionsIn a real-world setting, ss-RAB was associated with higher diagnostic yield and TIL rates compared with the VBN-based comparator arm without compromising safety. The observed benefit of ss-RAB was greater in lesion subgroups with higher procedural difficulty. In experienced centers, procedural performance with ss-RAB improved after a relatively short learning phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.